Q4FY23 marked a turnaround in Pfizer’s performance as the declining revenue trend (down 7% in FY23) was arrested in Q4, which saw a 4% YoY rise. The turnaround was driven by traction in key brands such as Magnex, Corex DX, Dolonex, Minipress XL and Prevenar-13.